Genetic Technologies Limited (GTG.AX)
-ASX 0.10 
0.00(4.04%) Jun 18
| Prev Close: | 0.10 |
|---|
| Open: | 0.10 |
|---|
| Bid: | 0.10 |
|---|
| Ask: | 0.10 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.10 - 0.10 |
|---|
| 52wk Range: | 0.06 - 0.15 |
|---|
| Volume: | 73,571 |
|---|
| Avg Vol (3m): | 319,050 |
|---|
| Market Cap: | 44.74M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- Genetic Technologies Provides U.S. Gene Patenting UpdateMarketwired(Sun, Jun 16)
- Genetic Technologies Executes Agreement With MultiPlan, Inc., a Nationwide Provider NetworkMarketwired(Mon, May 20)
- Genetic Technologies Executes Agreement With Nationwide Provider NetworkMarketwired(Fri, May 3)
- Genetic Technologies Announces Financial Results for Quarter Ended March 31, 2013Marketwired(Tue, Apr 30)
- Licensing Updateat Reuters(Tue, Mar 19)
- Genetic Technologies Provides U.S. Patent Re-Examination UpdateMarketwired(Fri, Mar 15)
- US patent re-examination updateat Reuters(Fri, Mar 15)
- Myriad Genetics Win on Gene Patent Ownership Is Appealedat Bloomberg(Sun, Mar 3)
- Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2012Marketwired(Fri, Feb 22)
- Myriad Genetics Wins Australia Bid to Patent Human Genesat Bloomberg(Thu, Feb 14)
- Genetic Technologies Appoints Chief Executive Officer and Non-Executive DirectorMarketwired(Mon, Dec 10)
- Appointment of permanent CEO and Non-Executive Directorat Reuters(Mon, Dec 10)
- Genetic Technologies Provides Update on Board and Management ChangesMarketwired(Thu, Nov 29)
- Appendix 3B – New issue announcement application for quotation of additional securities and agreementat Reuters(Mon, Oct 29)
- Cancellation of optionsat Reuters(Fri, Oct 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 13.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Genetic Technologies Limited provides genetic testing services. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and ...
View More